Search Results for citation:"89 FR 107148"

The Food and Drug Administration (FDA) has announced the renewal of the Dermatologic and Ophthalmic Drugs Advisory Committee, which will now operate until October 7, 2026. The committee provides expert advice on the safety and effectiveness of drugs used to treat skin and eye conditions, ensuring they are safe for human use. The committee is made up of professionals from various medical fields, including dermatology and ophthalmology, who are selected by the FDA Commissioner. This renewal highlights the FDA's commitment to maintaining expert oversight of drugs within this category.